p53 mutations in BRCA1-associated familial breast cancer [5]

Lancet

Volumn 350, Issue 9078, 1997, Pages 638-639

  Crook, Tim ^a   Crossland, Susan ^b   Crompton, Mark R ^b   Osin, Pinchas ^b   Gusterson, Barry A ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PARAFFIN;

BREAST CANCER; CELL CYCLE; DNA SEQUENCE; FAMILIAL CANCER; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LETTER; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 0030860404     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)63327-2     Document Type: Article

References (5)

1. Hakem R, de la Pomba JL, Sirard C, et al. The tumour suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse. Cell 1996; 85: 1009-23.
2. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-77.
3. Soussi T, Legros Y, Lubin R, et al. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994; 57: 1-9.
4. The Breast Cancer Linkage Consortium. The pathology of familial breast cancer: evidence for differences between breast cancers developing in carriers of BRCA1 mutations, BRCA2 mutations and sporadic cases. Lancet 1997; 349: 1505-10.
5. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad 51 in mitotic and meiotic cells. Cell 1997; 88: 265-75.